
May 29 (Reuters) - Lantern Pharma Inc LTRN.O:
LANTERN PHARMA'S LP-184 SHOWS PROMISING IN VIVO ACTIVITY IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT) AT SNO PEDIATRIC CONFERENCE, FURTHER VALIDATING RARE PEDIATRIC DISEASE DESIGNATION AND PATHWAY TO CLINICAL TRIALS